EASE study of AP 101 update of patient enrollment in Phase III trial for epidermolysis bullosa..-Amryt Pharma

EASE Trial of AP 101 from Amryt Pharma Update: In recent weeks, the COVID-19 pandemic has had a material impact on clinical trials globally, including patient recruitment. Given that the EASE study was already close to full enrollment, Amryt has taken advice from an independent expert and concluded that the statistical impact of further patient recruitment would most likely be negligible. Amryt has therefore decided to close the EASE study to further enrollment. Shortly after the last patient completes the end of the double-blind treatment period (Day 90), the study data will be cleaned and the database locked. Statistical analyses will then be performed and the Company now anticipates top line data read out in late Q3 / early Q4 2020.